Emphysema

Emphysema: A Specific Pattern, Not a Synonym for COPD

Emphysema is permanent damage to and destruction of the alveoli, the lungs’ tiny air sacs where oxygen and carbon dioxide are exchanged with the blood. As alveolar walls break down, they lose their normal elastic recoil, the property that helps push air back out with each breath, and can merge into larger, less efficient spaces.

The practical result is twofold: less surface area available for gas exchange, and a harder time fully emptying the lungs.

Emphysema relates closely to, but is not interchangeable with, COPD. It is one of two classic structural and clinical patterns that fall under the broader umbrella condition called COPD, alongside chronic bronchitis, and most people with COPD have some mixture of both patterns, in varying proportions, rather than a pure, textbook case of one or the other.

This page focuses on what’s specific to the emphysema pattern. For the broader disease overview, including the full range of causes and the general approach to COPD diagnosis and treatment, see the COPD overview linked above.

Emphysema vs. Chronic Bronchitis: Two Different Kinds of Damage

The two classic COPD patterns involve genuinely different tissue and different mechanisms, even though they often coexist in the same patient. Emphysema is damage deep in the lung, at the level of the alveoli. Chronic bronchitis is persistent inflammation and mucus production in the airways themselves, the tubes that carry air to and from the alveoli.

Emphysema vs. Chronic Bronchitis

Emphysema vs. Chronic Bronchitis

Dimension	Emphysema	Chronic Bronchitis
Site of Damage	The alveoli, where gas exchange with the blood happens	The airways that carry air to and from the alveoli
Underlying Process	Permanent destruction of alveolar walls	Persistent inflammation and mucus production
Clinical Definition	A structural and testing pattern rather than a fixed clinical rule	A cough productive of sputum on most days for at least 3 months a year, across 2 consecutive years
Typical DLCO	Classically reduced	Often relatively preserved
Typical Symptom Emphasis	Relatively less cough and sputum, as a generalization only	More prominent productive cough

Neither pattern excludes the other. A patient with a predominantly emphysematous CT scan can still have a productive cough, just as a patient with predominantly bronchitic symptoms can still have measurable alveolar damage on testing.

Why Emphysema Develops

Two points about the causes above are worth elaborating on. Occupational and environmental exposures act cumulatively over years of contact, in much the same way cigarette smoke’s damage accumulates with pack-years, which is part of why a detailed exposure history is a routine part of evaluating emphysema, particularly without a significant smoking history.

Alpha-1 antitrypsin deficiency is worth keeping in mind clinically, not simply as a rare footnote. It often presents earlier in life than typical smoking-related disease, sometimes in a person’s thirties or forties, and can preferentially affect the lower lung zones rather than the upper lungs, where smoking-related emphysema more typically concentrates.

That combination, an earlier age of onset or a limited smoking history plus a lower-zone pattern, is a genuinely helpful clinical clue that should prompt testing for alpha-1 antitrypsin deficiency, a simple blood test, rather than an assumption of typical disease.

Symptoms

The hallmark symptoms, progressive shortness of breath with exertion and reduced exercise tolerance, develop slowly enough that day-to-day changes can be easy to miss. Early on, breathlessness may only appear with real exertion, such as climbing stairs or carrying groceries; as alveolar damage accumulates, that threshold tends to drop, and once-routine activities start to require noticeably more effort.

A patient with a more purely emphysematous pattern may have relatively less cough and sputum production than one whose COPD is predominantly bronchitic, though this is a generalization rather than a reliable way to tell the two patterns apart on symptoms alone. Testing is what actually characterizes the underlying pattern, discussed below.

How Emphysema Is Identified

Identifying and characterizing emphysema typically moves through imaging, pulmonary function testing, and DLCO together, rather than relying on any single result in isolation.

Evaluating Suspected Emphysema

1. 01→Symptoms or Incidental FindingProgressive breathlessness prompts evaluation, or emphysema is noted incidentally on a chest CT done for another reason.↓
2. 02→Chest CT ImagingReveals areas of reduced lung density reflecting alveolar wall loss, and their distribution across lung zones.↓
3. 03Pulmonary Function TestingSpirometry typically shows airflow obstruction; lung volume testing often shows hyperinflation.↓
4. 04→DLCOMeasures gas transfer between the lungs and bloodstream; classically reduced in emphysema.↓
5. 05Physician SynthesisImaging, spirometry, lung volumes, and DLCO are weighed together to characterize the pattern and its severity.

Imaging

A chest CT can reveal characteristic low-density regions that reflect the loss of alveolar walls, helping a physician gauge whether damage is concentrated in the upper or lower lung zones, a distribution that can itself be a useful clue toward alpha-1 antitrypsin deficiency.

Findings are sometimes noted incidentally, on a scan done for another reason, before symptoms are prominent enough to prompt evaluation on their own; when that happens, it’s a reasonable trigger for pulmonary function testing even without significant symptoms yet.

Pulmonary Function Testing

Pulmonary function testing plays a central role. Spirometry typically shows airflow obstruction, consistent with COPD generally, while lung volume testing often shows hyperinflation, an enlarged resting lung volume that reflects the loss of elastic recoil characteristic of alveolar destruction.

Hyperinflation matters beyond simply confirming the diagnosis: an over-inflated resting lung volume leaves less room for the lungs to expand with activity, part of why exertion feels disproportionately effortful for many patients with significant emphysema.

DLCO

DLCO, a measurement of how well gas transfers from the lungs into the bloodstream, is particularly useful for distinguishing emphysema from other COPD patterns. Because emphysema destroys alveolar-capillary surface area, DLCO is classically reduced, often even before spirometry shows significant obstruction in earlier disease.

A physician weighs DLCO alongside spirometry, lung volumes, and imaging together, rather than any single result in isolation, to build a fuller picture of which pattern predominates and how advanced the disease is.

Treatment Principles

There is no treatment that reverses alveolar damage already done, which is part of why avoiding further exposure, particularly stopping smoking for those who currently smoke, is consistently emphasized as the single most impactful step available. Treatment overlaps substantially with COPD treatment generally; see the COPD overview for that fuller discussion rather than duplicating it here. The options below cover what deserves specific mention for emphysema.

Ongoing Care

Because emphysema reflects a structural change that has already occurred, ongoing management is less about a single decision and more about a sustained relationship with a care team: periodic reassessment of lung function and oxygen levels, and adjustment of treatment as symptoms or exacerbation patterns change.

Patients diagnosed at a younger age or with a genetic cause like alpha-1 antitrypsin deficiency benefit particularly from continuity with a pulmonologist familiar with their specific pattern of disease, rather than episodic care.